IRadimed Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IRadimed Corporation IRadimed Corporation (NASDAQ: IRMD) develops, manufactures, markets and distributes magnetic resonance imaging (MRI)-compatible medical devices, accessories, disposables and related services to hospitals, acute care facilities and endoscopy centers in the United States and internationally. The company offers the MRidium series of non-magnetic MRI IV infusion pump systems, including the MRidium 3860+ for continuous medication delivery during MRI procedures, the newly FDA-cleared MRidium 3870 next-generation infusion pump with enhanced touchscreen interface, graphical user interface, advanced safety features and multi-channel capabilities for critical care patients, and the 3880 MRI-compatible patient vital signs monitoring system featuring wireless ECG, SpO2, respiratory CO2, blood pressure and optional multi-gas anesthetic agent monitoring operable in magnetic fields up to 30,000 gauss; the FMD Smart MRI ferrous metal detector with TruSense threat qualification technology to reduce false alarms; proprietary disposable IV tubing sets; and associated maintenance and support services. Founded in 1992 and headquartered in Orlando, Florida, IRadimed Corporation maintains a leading market position as the sole provider of non-magnetic MRI infusion pumps and monitors, with operations focused on the medical devices sector serving high-acuity patients including those in ICU, anesthesia and pediatric care requiring uninterrupted monitoring and fluid delivery. Recent developments include FDA 510(k) clearance for the MRidium 3870 infusion pump system in May 2025, with limited commercial shipments commencing in December 2025 and full U.S. rollout in the first quarter of 2026; relocation to a new facility in Orlando amid transitional operational challenges; record Q3 2025 revenue of $21.2 million, a raised full-year revenue guidance to $82.5 million-$83.5 million, and a quarterly cash dividend declaration of $0.17 per share payable November 25, 2025; and participation in investor conferences such as the 2025 Wells Fargo Healthcare Conference.
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Why Iradimed Stock Topped the Market Today
iRadimed Corp (IRMD) Shares Surge 4.4% -- What GF Score of 95 Tells Investors
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock
Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
Principal Financial Group Inc. Acquires New Holdings in iRadimed Corporation $IRMD
IRadimed Stock Up 80% in One Year as Fund Sells $29 Million Stake Amid Record Quarter
Why Iradimed Stock Soared Today
IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
iRadimed Corporation (NASDAQ:IRMD) Given Average Rating of “Moderate Buy” by Analysts